IRTC IRhythm Technologies Inc.

iRhythm Technologies Announces CFO Transition

iRhythm Technologies Announces CFO Transition

SAN FRANCISCO, June 04, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today that Douglas Devine has been appointed Chief Financial Officer (CFO), effective June 22, 2020. Mr. Devine will succeed Matthew Garrett, who has decided to step down from the role. Mr. Garrett has agreed to assist in a well-ordered transition of his CFO responsibilities and will remain at iRhythm in an advisory role for up to a year to assist with special projects.

“On behalf of everyone at iRhythm and our Board of Directors, I want to thank Matt for his many contributions during his tenure with the company, including his strong leadership through iRhythm's IPO and follow-on offering, as well as numerous other transactions that enabled our growth and positioned us well for future financial stability,” said Kevin King, CEO. “We appreciate his dedication and wish him all the best beyond iRhythm.”

“It has been a privilege to serve as iRhythm’s CFO for the past seven and a half years, and to see the impact that we are making in fundamentally transforming how cardiac arrhythmias are diagnosed. I’m proud to have been part of this important healthcare advancement,” said Matthew Garrett. “It has also been an honor to have worked alongside colleagues that are truly dedicated to bringing to market superior solutions that improve the quality of life of our customers and their patients.”

Mr. King also stated, “I am delighted to welcome Doug to iRhythm. We are fortunate to have a strong finance team, and now a smooth transition plan in place with Doug immediately stepping into the CFO role. His expansive financial experience and track record leading large, complex technology organizations provides not only continuity for our team, but readily enables us to make the next stride forward in operational growth and financial performance.”

Douglas Devine brings more than 25 years of financial leadership experience to iRhythm, including a track record of success in fund raising, influencing business strategy, driving cost reductions, and implementing financial systems. He joins the company from GlobalFoundries, a multi-billion dollar semiconductor foundry, where he has been the Chief Financial Officer.

“iRhythm Technologies has impressed me with its team, culture, board, unique products and growth potential,” said Douglas Devine. “I’m very excited to join the team and look forward to exciting times ahead.”

Devine holds an MBA from the University of Michigan and a BS in Engineering from the University of Michigan. He also has earned his CPA certification.

About iRhythm Technologies, Inc.  iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the CFO transition and employment matters related thereto. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filing made with the Securities and Exchange Commission on the Form 10-Q on May 8, 2020. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:Media Contact:
Lynn Pieper Lewis or Leigh SalvoSaige Smith
(415) 937-5404(262) 289-7065



EN
04/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

Irhythm Technologies Inc: 1 director

A director at Irhythm Technologies Inc sold 5,000 shares at 175.000USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

 PRESS RELEASE

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial ...

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether home-based, self-applied use of iRhythm’s Zio long-term continuous monitoring (LTCM) device and service could improve diagnosis of atrial fibrillation (AFib) in 5040 participants in the United ...

 PRESS RELEASE

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time)Morgan Stanley Global Healthcare Conference 2025 on Tuesday, September 9, 2025, at 2:35 p.m. Eastern Time (11:35 a...

 PRESS RELEASE

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm...

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service’s value across patient populations and payer segments. SAN FRANCISCO, Aug....

 PRESS RELEASE

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution f...

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a digital health leader focused on creating trusted solut...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch